Livedoid vasculopathy in Koreans: clinical features and response to rivaroxaban treatment.

Abstract

Livedoid vasculopathy (LV) is a rare thrombo-occlusive disease which has a great impact on the patients' quality of life.1,2 Large-scale studies or studies including Asian population are scarce and there are still no established treatments for LV. Rivaroxaban, a direct factor Xa inhibitor, has demonstrated good effects in LV.1,3,4 Compared to other treatments such as classic anticoagulants or intravenous immunoglobulin, rivaroxaban is way more convenient since it does not require injection, international normalized ratio monitoring or hospitalization.